| Home : April 2011 : April 11, 2011 News : immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients |
immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients |
April 11, 2011
TUEBINGEN, Germany, April 11, 2011 /PRNewswire/ -- immatics
biotechnologies GmbH, a clinical-stage biopharmaceutical company developing
advanced therapeutic vaccines that are active against cancer, today announced
that Pfizer has agreed to support its pivotal Phase III trial (IMPRINT =
IMA901 Mu
http://www.prnewswire.com/news-releases/immatics-to-receive-support-from-pfizer-for-its-pivotal-phase-iii-study-imprint-with-ima901-a-therapeutic-vaccine-for-advanced-renal-cell-cancer-patients-119583849.html
|
|
|
 Other Stories |
|
|
|
|
|
|
|
|
|
|
|
